Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • OptimizeRx's Other Operating Expenses fell 8741.85% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 7932.21%. This contributed to the annual value of $23.2 million for FY2024, which is 118188.61% up from last year.
  • Latest data reveals that OptimizeRx reported Other Operating Expenses of $1.1 million as of Q3 2025, which was down 8741.85% from $1.1 million recorded in Q2 2025.
  • OptimizeRx's Other Operating Expenses' 5-year high stood at $18.4 million during Q4 2024, with a 5-year trough of -$8.6 million in Q1 2023.
  • Its 5-year average for Other Operating Expenses is $2.9 million, with a median of $1.1 million in 2025.
  • Data for OptimizeRx's Other Operating Expenses shows a peak YoY increase of 207592.33% (in 2023) and a maximum YoY decrease of 193059.76% (in 2023) over the last 5 years.
  • OptimizeRx's Other Operating Expenses (Quarter) stood at -$7.1 million in 2021, then soared by 326.9% to $16.2 million in 2022, then crashed by 91.72% to $1.3 million in 2023, then soared by 1270.27% to $18.4 million in 2024, then tumbled by 94.13% to $1.1 million in 2025.
  • Its Other Operating Expenses stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.